A combination of two Eli Lilly antibody drugs cut the risk of COVID-19-related hospitalizations and deaths by 87%, the company announced Wednesday, further upholding dosing already authorized by the Food and Drug Administration.

The findings draw from a BLAZE-1 Phase 3 cohort with 769 mild-to-moderate coronavirus patients aged 12 and up at high-risk of progressing to severe disease. There were 15 events like hospitalizations or deaths in the placebo group, and four events in a group of patients taking 700 mg of bamlanivimab and 1400 mg of etesevimab together, representing an 87 percent risk reduction, Lilly announced.

source: foxnews.com